Walsh, G. & Walsh, E. Biopharmaceutical benchmarks 2022. Nat. Biotechnol. 40, 1722–1760 (2022).
Google Scholar
Lu, R.-M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020).
Google Scholar
Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553–557 (1997).
Google Scholar
Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317 (1985).
Google Scholar
Strohl, W. R. & Strohl, L. M. Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry (Woodhead Publishing, 2012).
Hanes, J. & Plückthun, A. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl Acad. Sci. USA 94, 4937–4942 (1997).
Google Scholar
Ho, M., Nagata, S. & Pastan, I. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc. Natl Acad. Sci. USA 103, 9637–9642 (2006).
Google Scholar
Jin, B., Odongo, S., Radwanska, M. & Magez, S. NANOBODIES®: a review of diagnostic and therapeutic applications. Int. J. Mol. Sci. 24, 5994 (2023).
Google Scholar
Nessler, I. et al. Increased tumor penetration of single-domain antibody-drug conjugates improves in vivo efficacy in prostate cancer models. Cancer Res. 80, 1268–1278 (2020).
Google Scholar
Scully, M. et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 380, 335–346 (2019).
Google Scholar
Papadopoulos, K. P. et al. First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors. Oncologist 26, e1514–e1525 (2021).
Google Scholar
Oyama, S. et al. A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis. Sci. Rep. 12, 18102 (2022).
Google Scholar
Zhou, C. et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N. Engl. J. Med. 389, 2039–2051 (2023).
Google Scholar
Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974–977 (2008).
Google Scholar
Budde, L. E. et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 23, 1055–1065 (2022).
Google Scholar
Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220–2231 (2022).
Google Scholar
Thieblemont, C. et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J. Clin. Oncol. 41, 2238–2247 (2023).
Google Scholar
Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232–2244 (2022).
Google Scholar
Lesokhin, A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. 29, 2259–2267 (2023).
Google Scholar
Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 1721–1723 (2022).
Google Scholar
Klein, C., Brinkmann, U., Reichert, J. M. & Kontermann, R. E. The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug Discov. 23, 301–319 (2024).
Google Scholar
Wang, B., Gallolu Kankanamalage, S., Dong, J. & Liu, Y. Optimization of therapeutic antibodies. Antib. Ther. 4, 45–54 (2021).
Makowski, E. K. et al. Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning. Nat. Biomed. Eng. 8, 45–56 (2023).
Google Scholar
Teixeira, A. A. R. et al. Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs. mAbs 14, 2115200 (2022).
Google Scholar
Azevedo Reis Teixeira, A. et al. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries. mAbs 13, 1980942 (2021).
Google Scholar
Kelly, R. L., Le, D., Zhao, J. & Wittrup, K. D. Reduction of nonspecificity motifs in synthetic antibody libraries. J. Mol. Biol. 430, 119–130 (2018).
Google Scholar
Erasmus, M. F. et al. Developing drug-like single-domain antibodies (VHH) from in vitro libraries. mAbs 17, 2516676 (2025).
Google Scholar
Zhang, Y. Evolution of phage display libraries for therapeutic antibody discovery. mAbs 15, 2213793 (2023).
Google Scholar
Valadon, P. et al. ALTHEA Gold LibrariesTM: antibody libraries for therapeutic antibody discovery. mAbs 11, 516–531 (2019).
Google Scholar
Pang, G. et al. A synthetic heavy chain variable domain antibody library (VHL) provides highly functional antibodies with favorable developability. Protein Sci. 34, e70090 (2025).
Google Scholar
Xu, Y. et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng. Des. Sel. 26, 663–670 (2013).
Google Scholar
Traxlmayr, M. W. & Obinger, C. Directed evolution of proteins for increased stability and expression using yeast display. Arch. Biochem. Biophys. 526, 174–180 (2012).
Google Scholar
Makowski, E. K. et al. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space. Nat. Commun. 13, 3788 (2022).
Google Scholar
Dyson, M. R. et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. mAbs 12, 1829335 (2020).
Google Scholar
Huhtinen, O., Salbo, R., Lamminmäki, U. & Prince, S. Selection of biophysically favorable antibody variants using a modified Flp-In CHO mammalian display platform. Front. Bioeng. Biotechnol. 11, 1170081 (2023).
Google Scholar
Lippow, S. M., Wittrup, K. D. & Tidor, B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat. Biotechnol. 25, 1171–1176 (2007).
Google Scholar
Warszawski, S. et al. Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces. PLoS Comput. Biol. 15, e1007207 (2019).
Google Scholar
Sormanni, P., Aprile, F. A. & Vendruscolo, M. The CamSol method of rational design of protein mutants with enhanced solubility. J. Mol. Biol. 427, 478–490 (2015).
Google Scholar
Dreyer, F. A. et al. Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutations. mAbs 17, 2511220 (2025).
Google Scholar
Dauparas, J. et al. Robust deep learning–based protein sequence design using ProteinMPNN. Science 378, 49–56 (2022).
Google Scholar
Hie, B. L. et al. Efficient evolution of human antibodies from general protein language models. Nat. Biotechnol. 42, 275–283 (2024).
Google Scholar
Shanker, V. R., Bruun, T. U. J., Hie, B. L. & Kim, P. S. Unsupervised evolution of protein and antibody complexes with a structure-informed language model. Science 385, 46–53 (2024).
Google Scholar
Ramon, A. et al. Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV. Nat. Mach. Intell. 6, 74–91 (2024).
Google Scholar
Mason, D. M. et al. Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning. Nat. Biomed. Eng. 5, 600–612 (2021).
Google Scholar
Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449–W454 (2020).
Google Scholar
Rabia, L. A., Desai, A. A., Jhajj, H. S. & Tessier, P. M. Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility. Biochem. Eng. J. 137, 365–374 (2018).
Google Scholar
Alley, E. C., Khimulya, G., Biswas, S., AlQuraishi, M. & Church, G. M. Unified rational protein engineering with sequence-based deep representation learning. Nat. Methods 16, 1315–1322 (2019).
Google Scholar
Ministro, J., Manuel, A. M. & Goncalves, J. in Current Applications of Pharmaceutical Biotechnology, Vol. 171 (eds Silva, A. C. et al.) 55–86 (Springer, 2019).
Steinitz, M. Human Monoclonal Antibodies: Methods and Protocols (Humana Press, 2014).
Bachas, S. et al. Antibody optimization enabled by artificial intelligence predictions of binding affinity and naturalness. Preprint at bioRxiv https://doi.org/10.1101/2022.08.16.504181 (2022).
Liu, Y. et al. RoBERTa: a robustly optimized BERT pretraining approach. Preprint at https://doi.org/10.48550/arXiv.1907.11692 (2019).
Kovaltsuk, A. et al. Observed Antibody Space: a resource for data mining next-generation sequencing of antibody repertoires. J. Immunol. 201, 2502–2509 (2018).
Google Scholar
Olsen, T. H., Boyles, F. & Deane, C. M. Observed Antibody Space: a diverse database of cleaned, annotated, and translated unpaired and paired antibody sequences. Protein Sci. 31, 141–146 (2022).
Google Scholar
Prihoda, D. et al. BioPhi: a platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning. mAbs 14, 2020203 (2022).
Google Scholar
Chinery, L., Jeliazkov, J. R. & Deane, C. M. Humatch – fast, gene-specific joint humanisation of antibody heavy and light chains. mAbs 16, 2434121 (2024).
Google Scholar
Tennenhouse, A. et al. Computational optimization of antibody humanness and stability by systematic energy-based ranking. Nat. Biomed. Eng. 8, 30–44 (2023).
Google Scholar
Pavlinkova, G. et al. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs. Int. J. Cancer 94, 717–726 (2001).
Google Scholar
Lazar, G. A., Desjarlais, J. R., Jacinto, J., Karki, S. & Hammond, P. W. A molecular immunology approach to antibody humanization and functional optimization. Mol. Immunol. 44, 1986–1998 (2007).
Google Scholar
Safdari, Y., Farajnia, S., Asgharzadeh, M. & Khalili, M. Antibody humanization methods – a review and update. Biotechnol. Genet. Eng. Rev. 29, 175–186 (2013).
Google Scholar
Marks, C., Hummer, A. M., Chin, M. & Deane, C. M. Humanization of antibodies using a machine learning approach on large-scale repertoire data. Bioinformatics 37, 4041–4047 (2021).
Google Scholar
Filipe, V. et al. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. mAbs 4, 740–752 (2012).
Google Scholar
Harris, C. T. & Cohen, S. Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies. BioDrugs 38, 205–226 (2024).
Google Scholar
Starr, C. G. et al. Ultradilute measurements of self-association for the identification of antibodies with favorable high-concentration solution properties. Mol. Pharm. 18, 2744–2753 (2021).
Google Scholar
Makowski, E. K., Wu, L., Desai, A. A. & Tessier, P. M. Highly sensitive detection of antibody nonspecific interactions using flow cytometry. mAbs 13, 1951426 (2021).
Google Scholar
Saka, K. et al. Antibody design using LSTM based deep generative model from phage display library for affinity maturation. Sci. Rep. 11, 5852 (2021).
Google Scholar
Jiskoot, W., Hawe, A., Menzen, T., Volkin, D. B. & Crommelin, D. J. A. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: quo vadis? J. Pharm. Sci. 111, 861–867 (2022).
Google Scholar
Davis, J. D. et al. Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development. Clin. Pharmacol. Ther. 115, 422–439 (2024).
Google Scholar
Ma, H., Ó’Fágáin, C. & O’Kennedy, R. Antibody stability: a key to performance – analysis, influences and improvement. Biochimie 177, 213–225 (2020).
Google Scholar
Rosace, A. et al. Automated optimisation of solubility and conformational stability of antibodies and proteins. Nat. Commun. 14, 1937 (2023).
Google Scholar
Schymkowitz, J. et al. The FoldX web server: an online force field. Nucleic Acids Res. 33, W382–W388 (2005).
Google Scholar
Leaver-Fay, A. et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545–574 (2011).
Google Scholar
Dreyer, F. A., Cutting, D., Schneider, C., Kenlay, H. & Deane, C. M. Inverse folding for antibody sequence design using deep learning. Preprint at https://doi.org/10.48550/arXiv.2310.19513 (2023).
Raybould, M. I. J. et al. Five computational developability guidelines for therapeutic antibody profiling. Proc. Natl Acad. Sci. USA 116, 4025–4030 (2019).
Google Scholar
Aguilar Rangel, M. et al. Fragment-based computational design of antibodies targeting structured epitopes. Sci. Adv. 8, eabp9540 (2022).
Google Scholar
Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235–242 (2000).
Google Scholar
Dunbar, J. et al. SAbDab: the structural antibody database. Nucleic Acids Res. 42, D1140–D1146 (2014).
Google Scholar
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
Google Scholar
Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089–1100 (2023).
Google Scholar
Bennett, N. R. et al. Atomically accurate de novo design of antibodies with RFdiffusion. Nature 649, 183–193 (2026).
Google Scholar
Baek, M. et al. Efficient and accurate prediction of protein structure using RoseTTAFold2. Preprint at bioRxiv https://doi.org/10.1101/2023.05.24.542179 (2023).
Douthwaite, J. A., Finch, D. K., Mustelin, T. & Wilkinson, T. C. I. Development of therapeutic antibodies to G protein-coupled receptors and ion channels: opportunities, challenges and their therapeutic potential in respiratory diseases. Pharmacol. Ther. 169, 113–123 (2017).
Google Scholar
Hutchings, C. J. Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels. Antib. Ther. 3, 257–264 (2020).
Stephens, A. D. & Wilkinson, T. Discovery of therapeutic antibodies targeting complex multi-spanning membrane proteins. BioDrugs 38, 769–794 (2024).
Google Scholar
Dodd, R., Schofield, D. J., Wilkinson, T. & Britton, Z. T. Generating therapeutic monoclonal antibodies to complex multi-spanning membrane targets: overcoming the antigen challenge and enabling discovery strategies. Methods 180, 111–126 (2020).
Google Scholar
Nabla Bio & Biswas, S. De novo design of hundreds of functional GPCR-targeting antibodies enabled by scaling test-time compute. Preprint at bioRxiv https://doi.org/10.1101/2025.05.28.656709 (2025).
Wossnig, L., Furtmann, N., Buchanan, A., Kumar, S. & Greiff, V. Best practices for machine learning in antibody discovery and development. Drug Discov. Today 29, 104025 (2024).
Google Scholar
Matsunaga, R. & Tsumoto, K. Accelerating antibody discovery and optimization with high-throughput experimentation and machine learning. J. Biomed. Sci. 32, 46 (2025).
Google Scholar
Chen, H.-T. et al. Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions. Cell Rep. 43, 114801 (2024).
Google Scholar
Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Molina-Abad, E. & Moreno, E. NbThermo: a new thermostability database for nanobodies. Database 2023, baad021 (2023).
Google Scholar
Raybould, M. I. J., Kovaltsuk, A., Marks, C. & Deane, C. M. CoV-AbDab: the coronavirus antibody database. Bioinformatics 37, 734–735 (2021).
Google Scholar
Liu, C. et al. AbRank: a benchmark dataset and metric-learning framework for antibody-antigen affinity ranking. Preprint at https://doi.org/10.48550/arXiv.2506.17857 (2025).
Jain, T. et al. Biophysical properties of the clinical-stage antibody landscape. Proc. Natl Acad. Sci. USA 114, 944–949 (2017).
Google Scholar
Erasmus, M. F. et al. AIntibody: an experimentally validated in silico antibody discovery design challenge. Nat. Biotechnol. 42, 1637–1642 (2024).
Google Scholar
Minot, M. & Reddy, S. T. Meta learning addresses noisy and under-labeled data in machine learning-guided antibody engineering. Cell Syst. 15, 4–18.e4 (2024).
Google Scholar
Ursu, E. et al. Training data composition determines machine learning generalization and biological rule discovery. Nat. Mach. Intell. 7, 1206–1219 (2025).
Google Scholar
Manso, T. et al. IMGT® databases, related tools and web resources through three main axes of research and development. Nucleic Acids Res. 50, D1262–D1272 (2022).
Google Scholar
Shanehsazzadeh, A. et al. Unlocking de novo antibody design with generative artificial intelligence. Preprint at bioRxiv https://doi.org/10.1101/2023.01.08.523187 (2023).
Lin, Z. et al. Evolutionary-scale prediction of atomic-level protein structure with a language model. Science 379, 1123–1130 (2023).
Google Scholar
Suzek, B. E. et al. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. Bioinformatics 31, 926–932 (2015).
Google Scholar
Devlin, J., Chang, M.-W., Lee, K. & Toutanova, K. BERT: pre-training of deep bidirectional transformers for language understanding. Preprint at https://doi.org/10.48550/arXiv.1810.04805 (2018).
Yu, X. et al. Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies. Antib. Ther. 7, 199–208 (2024).
Elnaggar, A. et al. ProtTrans: toward understanding the language of life through self-supervised learning. IEEE Trans. Pattern Anal. Mach. Intell. 44, 7112–7127 (2022).
Google Scholar
Steinegger, M. & Söding, J. Clustering huge protein sequence sets in linear time. Nat. Commun. 9, 2542 (2018).
Google Scholar
Steinegger, M., Mirdita, M. & Söding, J. Protein-level assembly increases protein sequence recovery from metagenomic samples manyfold. Nat. Methods 16, 603–606 (2019).
Google Scholar
Rollins, Z. A., Widatalla, T., Waight, A., Cheng, A. C. & Metwally, E. AbLEF: antibody language ensemble fusion for thermodynamically empowered property predictions. Bioinformatics 40, btae268 (2024).
Google Scholar
Olsen, T. H., Moal, I. H. & Deane, C. M. AbLang: an antibody language model for completing antibody sequences. Bioinform. Adv. 2, vbac046 (2022).
Google Scholar
Olsen, T. H., Moal, I. H. & Deane, C. M. Addressing the antibody germline bias and its effect on language models for improved antibody design. Bioinformatics 40, btae618 (2024).
Google Scholar
Shuai, R. W., Ruffolo, J. A. & Gray, J. J. IgLM: Infilling language modeling for antibody sequence design. Cell Syst. 14, 979–989.e4 (2023).
Google Scholar
Radford, A. et al. Language Models Are Unsupervised Multitask Learners https://cdn.openai.com/better-language-models/language_models_are_unsupervised_multitask_learners.pdf (2019).
Ruffolo, J. A., Gray, J. J. & Sulam, J. Deciphering antibody affinity maturation with language models and weakly supervised learning. Preprint at https://doi.org/10.48550/arXiv.2112.07782 (2021).
Wang, H., Hao, X., He, Y. & Fan, L. AbImmPred: an immunogenicity prediction method for therapeutic antibodies using antiBERTy-based sequence features. PLoS ONE 19, e0296737 (2024).
Google Scholar
Leem, J., Mitchell, L. S., Farmery, J. H. R., Barton, J. & Galson, J. D. Deciphering the language of antibodies using self-supervised learning. Patterns 3, 100513 (2022).
Google Scholar
Hsu, C. et al. Learning inverse folding from millions of predicted structures. Preprint at bioRxiv https://doi.org/10.1101/2022.04.10.487779 (2022).
Orengo, C. A. et al. CATH—a hierarchic classification of protein domain structures. Structure 5, 1093–1108 (1997).
Google Scholar
Abanades, B. et al. ImmuneBuilder: deep-learning models for predicting the structures of immune proteins. Commun. Biol. 6, 575 (2023).
Google Scholar
Høie, M. H. et al. AntiFold: improved structure-based antibody design using inverse folding. Bioinform. Adv. 5, vbae202 (2025).
Google Scholar
Turnbull, O. M., Oglic, D., Croasdale-Wood, R. & Deane, C. M. p-IgGen: a paired antibody generative language model. Bioinformatics 40, btae659 (2024).
Google Scholar
UniProt: the universal protein knowledgebase in 2025. Nucleic Acids Res. 53, D609–D617 (2025).
Adams, R. et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front. Immunol. 11, 1894 (2020).
Google Scholar
Shi, J., Baker, T., Lawson, A. D. G. & Liu, X. Obtaining an improved therapeutic ligand. WIPO patent WO2014198951A2 (2014).
Rasco, D. W. et al. Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors. J. Clin. Oncol. 42, 2527–2527 (2024).
Google Scholar
Ofran, Y., Nimrod, G., Fischman, S. & Herman, A. Computer assisted antibody re-epitoping. WIPO patent WO2016086185A1 (2016).
Chen, C., Garcia, Z., Chen, D., Liu, H. & Trelstad, P. Cost and supply considerations for antibody therapeutics. mAbs 17, 2451789 (2025).
Google Scholar
DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
Google Scholar
Hummer, A. M., Schneider, C., Chinery, L. & Deane, C. M. Investigating the volume and diversity of data needed for generalizable antibody–antigen ΔΔG prediction. Nat. Comput. Sci. 5, 635–647 (2025).
Google Scholar
